A Phase 1b Trial of Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Patients With Hematological Malignancies
Magrolimab, a monoclonal antibody targeting CD47, is being evaluated for its safety and efficacy in treating hematological malignancies, specifically acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). The market for AML and MDS therapies is significant, with a growing demand for innovative treatments due to the high unmet need in relapsed/refractory cases. The discontinuation of this trial due to futility, based on the results of the ENHANCE trial, raises concerns about the competitive positioning of magrolimab against existing and emerging therapies in this space. The findings may impact Gilead Sciences' strategic direction and investment in CD47-targeting therapies.
Indication: Hematological Malignancies
Modality: small molecule
Target: CD47
Sponsor: Gilead Sciences
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jun 23, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: CD47
View original source fields
Condition raw: Hematological Malignancies
Condition normalized: Hematological Malignancies
Modality raw: small molecule
Modality normalized: small molecule
Target raw: CD47
Target normalized: CD47